Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months

NCT05584202 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05584202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05584202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Two-Part Study (Open-Label [Part 1] Followed by Observer-Blind/Randomized [Part 2]) to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 Vaccine in Participants Aged 12 Weeks to < 6 Months
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2022
Completion date
November 15, 2024
Enrollment
68 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2